Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16992311 | 0.85 | CYP2C9 (0.52) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 | |
| SCHEMBL18429066 | 0.85 | USP2 (0.41) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 | |
| SCHEMBL18075919 | 0.81 | CYP1A2 (0.45) | CYP3A4CYP1A2ALDH1A1TSHRMEN1 | |
| SCHEMBL6114857 | 0.79 | USP2 (0.43) | USP2 | |
| SCHEMBL19504452 | 0.75 | USP2 (0.56) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 | |
| SCHEMBL29424710 | 0.75 | CYP2C9 (0.57) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 | |
| SCHEMBL30745944 | 0.75 | CYP2C9 (0.57) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 | |
| SCHEMBL23091753 | 0.74 | POLB (0.49) | CYP3A4CYP2C19CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL21655377 | 0.74 | CYP3A4 (0.38) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 | |
| SCHEMBL21358327 | 0.73 | CHRNB2 (0.47) | USP2CYP3A4CYP2C19HSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | USP2 1711/4885CYP3A4 856/4885CYP2C19 558/4885 |
| US-20230227438-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPAR1, LPL | USP2 1781/4885CYP3A4 980/4885CYP2C19 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.